These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 12874007)
1. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Mansour AM; Drevs J; Esser N; Hamada FM; Badary OA; Unger C; Fichtner I; Kratz F Cancer Res; 2003 Jul; 63(14):4062-6. PubMed ID: 12874007 [TBL] [Abstract][Full Text] [Related]
2. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen. Kratz F; Mansour A; Soltau J; Warnecke A; Fichtner I; Unger C; Drevs J Arch Pharm (Weinheim); 2005 Oct; 338(10):462-72. PubMed ID: 16211657 [TBL] [Abstract][Full Text] [Related]
3. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599 [TBL] [Abstract][Full Text] [Related]
4. Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates. Kratz F; Drevs J; Bing G; Stockmar C; Scheuermann K; Lazar P; Unger C Bioorg Med Chem Lett; 2001 Aug; 11(15):2001-6. PubMed ID: 11454467 [TBL] [Abstract][Full Text] [Related]
5. Metalloprotease-specific poly(ethylene glycol) methyl ether-peptide-doxorubicin conjugate for targeting anticancer drug delivery based on angiogenesis. Bae M; Cho S; Song J; Lee GY; Kim K; Yang J; Cho K; Kim SY; Byun Y Drugs Exp Clin Res; 2003; 29(1):15-23. PubMed ID: 12866360 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP). Graeser R; Chung DE; Esser N; Moor S; Schächtele C; Unger C; Kratz F Int J Cancer; 2008 Mar; 122(5):1145-54. PubMed ID: 17973264 [TBL] [Abstract][Full Text] [Related]
7. Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies. Trouet A; Passioukov A; Van derpoorten K; Fernandez AM; Abarca-Quinones J; Baurain R; Lobl TJ; Oliyai C; Shochat D; Dubois V Cancer Res; 2001 Apr; 61(7):2843-6. PubMed ID: 11306455 [TBL] [Abstract][Full Text] [Related]
8. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Wu W; Luo Y; Sun C; Liu Y; Kuo P; Varga J; Xiang R; Reisfeld R; Janda KD; Edgington TS; Liu C Cancer Res; 2006 Jan; 66(2):970-80. PubMed ID: 16424032 [TBL] [Abstract][Full Text] [Related]
9. Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA). Chung DE; Kratz F Bioorg Med Chem Lett; 2006 Oct; 16(19):5157-63. PubMed ID: 16875815 [TBL] [Abstract][Full Text] [Related]
10. Microtubule-dependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion. Schnaeker EM; Ossig R; Ludwig T; Dreier R; Oberleithner H; Wilhelmi M; Schneider SW Cancer Res; 2004 Dec; 64(24):8924-31. PubMed ID: 15604254 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B. Warnecke A; Fichtner I; Sass G; Kratz F Arch Pharm (Weinheim); 2007 Aug; 340(8):389-95. PubMed ID: 17628030 [TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin. Unger C; Häring B; Medinger M; Drevs J; Steinbild S; Kratz F; Mross K Clin Cancer Res; 2007 Aug; 13(16):4858-66. PubMed ID: 17699865 [TBL] [Abstract][Full Text] [Related]
13. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors. Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390 [TBL] [Abstract][Full Text] [Related]
14. Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting. Terada T; Iwai M; Kawakami S; Yamashita F; Hashida M J Control Release; 2006 Apr; 111(3):333-42. PubMed ID: 16488046 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin. Legigan T; Clarhaut J; Renoux B; Tranoy-Opalinski I; Monvoisin A; Berjeaud JM; Guilhot F; Papot S J Med Chem; 2012 May; 55(9):4516-20. PubMed ID: 22515366 [TBL] [Abstract][Full Text] [Related]
16. Development of albumin-binding camptothecin prodrugs using a Peptide positional scanning library. Schmid B; Warnecke A; Fichtner I; Jung M; Kratz F Bioconjug Chem; 2007; 18(6):1786-99. PubMed ID: 17915955 [TBL] [Abstract][Full Text] [Related]
17. [Involvement of matrix metalloproteinases (MMPs) in cutaneous melanoma progression]. Ntayi C; Hornebeck W; Bernard P Pathol Biol (Paris); 2004 Apr; 52(3):154-9. PubMed ID: 15063935 [TBL] [Abstract][Full Text] [Related]
18. A macromolecular prodrug of doxorubicin conjugated to a biodegradable cyclotriphosphazene bearing a tetrapeptide. Kim JK; Toti US; Song R; Sohn YS Bioorg Med Chem Lett; 2005 Aug; 15(15):3576-9. PubMed ID: 15982876 [TBL] [Abstract][Full Text] [Related]
19. Depsipeptide a histone deacetlyase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549). Vinodhkumar R; Song YS; Ravikumar V; Ramakrishnan G; Devaki T Chem Biol Interact; 2007 Feb; 165(3):220-9. PubMed ID: 17240363 [TBL] [Abstract][Full Text] [Related]
20. Poly (ethylene glycol) prodrug for anthracyclines via N-Mannich base linker: design, synthesis and biological evaluation. Zhao YJ; Wei W; Su ZG; Ma GH Int J Pharm; 2009 Sep; 379(1):90-9. PubMed ID: 19540322 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]